stock
Immunitybio Inc
NASDAQ | IBRX
2.82
USD
+0.00
(+0.00%
)AT CLOSE (AS OF Aug 13, 2025)
$2.3B
MARKET CAP
-
P/E Ratio
-0.48
EPS
$7.5
52 Week High
$1.8
52 Week Low
LIFE SCIENCES
Sector
IBRX Chart
Recent Chart
Price Action
1D
Candles
Trade Smarter
Automate your trading workflow with powerful tools — built for serious traders.
IBRX Technicals
IBRX Earnings
Yearly Income Statement (As of Dec 31, 2024)
| Field | Value (USD) |
|---|---|
| Gross Profit | $15M |
| Total Revenue | $15M |
| Cost Of Revenue | $18M |
| Costof Goods And Services Sold | $18M |
| Operating Income | -$344M |
| Selling General And Administrative | $169M |
| Research And Development | $190M |
| Operating Expenses | $359M |
| Investment Income Net | - |
| Net Interest Income | -$152M |
| Interest Income | $2.4M |
| Interest Expense | $154M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $18M |
| Income Before Tax | -$414M |
| Income Tax Expense | $81K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$414M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$259M |
| Ebitda | -$242M |
| Net Income | -$414M |
Revenue & Profitability
Earnings Performance
IBRX Financials
yearly Balance Sheet (As of Dec 31, 2024)
| Field | Value (USD) |
|---|---|
| Total Assets | $383M |
| Total Current Assets | $185M |
| Cash And Cash Equivalents At Carrying Value | $143M |
| Cash And Short Term Investments | $143M |
| Inventory | $8.3M |
| Current Net Receivables | $2.7M |
| Total Non Current Assets | $198M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $15M |
| Intangible Assets Excluding Goodwill | $15M |
| Goodwill | $910K |
| Investments | - |
| Long Term Investments | $0 |
| Short Term Investments | $6.4M |
| Other Current Assets | $24M |
| Other Non Current Assets | - |
| Total Liabilities | $871M |
| Total Current Liabilities | $55M |
| Current Accounts Payable | $6.7M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $8.7M |
| Total Non Current Liabilities | $816M |
| Capital Lease Obligations | $42M |
| Long Term Debt | $462M |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $504M |
| Other Current Liabilities | $39M |
| Other Non Current Liabilities | $285M |
| Total Shareholder Equity | -$488M |
| Treasury Stock | - |
| Retained Earnings | -$3.4B |
| Common Stock | $85K |
| Common Stock Shares Outstanding | $700M |
yearly Cash Flow (As of Dec 31, 2024)
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$391M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $18M |
| Capital Expenditures | $6.9M |
| Change In Receivables | - |
| Change In Inventory | -$8.3M |
| Profit Loss | - |
| Cashflow From Investment | -$12M |
| Cashflow From Financing | $282M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$414M |
yearly Income Statement (As of Dec 31, 2024)
| Field | Value (USD) |
|---|---|
| Gross Profit | $15M |
| Total Revenue | $15M |
| Cost Of Revenue | $18M |
| Costof Goods And Services Sold | $18M |
| Operating Income | -$344M |
| Selling General And Administrative | $169M |
| Research And Development | $190M |
| Operating Expenses | $359M |
| Investment Income Net | - |
| Net Interest Income | -$152M |
| Interest Income | $2.4M |
| Interest Expense | $154M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $18M |
| Income Before Tax | -$414M |
| Income Tax Expense | $81K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$414M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$259M |
| Ebitda | -$242M |
| Net Income | -$414M |
IBRX News
IBRX Profile
Immunitybio Inc Profile
Sector: LIFE SCIENCES
Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
ImmunityBio, Inc., an immunotherapy company, develops a memory T-cell cancer vaccine to fight multiple types of tumors without the use of high-dose chemotherapy.
Discover more tools and features to empower your trading
Explore FeaturesMarket data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.